1. Home
  2. INGN vs CHRS Comparison

INGN vs CHRS Comparison

Compare INGN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inogen Inc

INGN

Inogen Inc

HOLD

Current Price

$6.31

Market Cap

177.1M

Sector

Health Care

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

N/A

Current Price

$1.46

Market Cap

209.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INGN
CHRS
Founded
2001
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.1M
209.8M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
INGN
CHRS
Price
$6.31
$1.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$11.25
$5.51
AVG Volume (30 Days)
195.1K
760.7K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
43.42
472.00
EPS
N/A
N/A
Revenue
$348,668,000.00
N/A
Revenue This Year
$8.03
$73.08
Revenue Next Year
$7.76
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
3.86
N/A
52 Week Low
$5.34
$0.81
52 Week High
$9.13
$2.62

Technical Indicators

Market Signals
Indicator
INGN
CHRS
Relative Strength Index (RSI) 48.07 49.00
Support Level $6.00 $1.38
Resistance Level $6.73 $1.76
Average True Range (ATR) 0.24 0.07
MACD -0.03 -0.00
Stochastic Oscillator 41.79 31.82

Price Performance

Historical Comparison
INGN
CHRS

About INGN Inogen Inc

Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: